Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
GANX Stock Chart & Stats
$2.43
-$0.01(-0.44%)
At close: 4:00 PM EST
$2.43
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)700.34K
Market Cap
$96.92M
Enterprise Value$88.72M
Total Cash (Recent Filing)$8.81M
Total Debt (Recent Filing)$605.28K
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding38,462,086
10 Day Avg. Volume804,494
30 Day Avg. Volume700,343
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.73
Price to Sales (P/S)0.00
P/FCF Ratio-2.62
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-17.78
Enterprise Value/Ebitda-5.10
Forecast
1Y Price Target
$7.50Price Target Upside208.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceReduction in cerebrospinal fluid glucosylsphingosine demonstrates central nervous system target engagement, providing clinical evidence that the therapy lowers a toxic substrate linked to Parkinson's pathology.
Clinical Development ProgressSubmission of an investigational new drug application and readiness for a Phase 2 dose-finding trial enable advancement to a controlled study to define dosing and confirm effects pending regulatory clearance.
Mechanism And Early SafetyAn oral, brain-penetrant allosteric modulator showed favorable safety, central nervous system penetration, and target engagement in early healthy volunteer data, supporting feasibility for development as a potential disease-modifying therapy.
Bears Say
Market And Financing RiskMarked share price volatility around data announcements and expectations of a capital raise heighten downside risk from profit-taking and potential shareholder dilution.
Study Design LimitationsOpen-label, small and brief Phase 1b design limits confidence in findings and requires larger randomized trials to validate the reported effects.
Uncertain Clinical BenefitObserved biomarker improvements have not been shown to produce meaningful patient benefit, leaving the link between target engagement and clinical outcomes unproven until controlled studies report functional results.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics’s market cap?
Gain Therapeutics’s market cap is $96.92M.
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 2 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.161 by $0.011.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 38,462,086 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.161. Following the earnings report the stock price went up 10.075%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (208.64% Upside)
$7.50 (208.64% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.45%
12-Months-Change
Fundamentals
Return on Equity
-341.33%
Trailing 12-Months
Asset Growth
-23.63%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.50
▲(208.64% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.33%
Insiders
1.80% Mutual Funds
4.75% Other Institutional Investors
88.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---